For more than 20 years, scientists have been working on harnessing the disease fighting capability in a genuine way which has beneficial results for cancer patients, notably the prolongation of survival, Kantoff said. Our research provides proof that this approach can work. Unlike preventive vaccines, which strengthen the immune system to protect people from contracting a sickness, Provenge can be an autologous cellular immunotherapy, or a therapeutic vaccine, that marshals the immune system’s disease-fighting forces for those who already have prostate cancers. The immunotherapy is produced by removing some of a patient’s white bloodstream cells – a process called leukapheresis – and exposing them to a protein from prostate tumor cells and a stimulatory molecule.Related StoriesAmputation isn’t wound healingVISERA 4K UHD endoscopy system gives surgeons 4x resolutionMelatonin and the circadian rhythm: an interview with Professor Kennaway, University of AdelaideThe importance of his research lies in the multiple benefits of this fluid in regards to to others. Pericardial liquid can be plasma ultrafiltered from the serous vessel surrounding the center, a watertight compartment separated from blood.